Business Description
Dabomb Protein Biotech Corp
ISIN : TW0006578008
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.3 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | 8.48 | |||||
Interest Coverage | 0.57 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.34 | |||||
Beneish M-Score | -3.01 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -26.7 | |||||
3-Year FCF Growth Rate | -16 | |||||
3-Year Book Growth Rate | -8.2 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 22.9 | |||||
9-Day RSI | 28.74 | |||||
14-Day RSI | 30.55 | |||||
6-1 Month Momentum % | -29.82 | |||||
12-1 Month Momentum % | -7.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.87 | |||||
Quick Ratio | 2.75 | |||||
Cash Ratio | 1.42 | |||||
Days Inventory | 32.56 | |||||
Days Sales Outstanding | 42.21 | |||||
Days Payable | 15.99 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.77 | |||||
Dividend Payout Ratio | 3.92 | |||||
3-Year Dividend Growth Rate | 14.2 | |||||
Forward Dividend Yield % | 2.77 | |||||
5-Year Yield-on-Cost % | 2.74 | |||||
3-Year Average Share Buyback Ratio | -20.9 | |||||
Shareholder Yield % | 17.67 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 20.3 | |||||
Operating Margin % | 1.02 | |||||
Net Margin % | 2.02 | |||||
FCF Margin % | 1.59 | |||||
ROE % | 0.73 | |||||
ROA % | 0.52 | |||||
ROIC % | 0.27 | |||||
ROC (Joel Greenblatt) % | 1.86 | |||||
ROCE % | 1.51 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 143.08 | |||||
PE Ratio without NRI | 143.08 | |||||
Shiller PE Ratio | 30.74 | |||||
PS Ratio | 3.47 | |||||
PB Ratio | 1.22 | |||||
Price-to-Tangible-Book | 1.21 | |||||
Price-to-Free-Cash-Flow | 453.66 | |||||
Price-to-Operating-Cash-Flow | 49.47 | |||||
EV-to-EBIT | 70.44 | |||||
EV-to-EBITDA | 38.77 | |||||
EV-to-Revenue | 3.29 | |||||
EV-to-FCF | 209.05 | |||||
Price-to-Projected-FCF | 36.8 | |||||
Price-to-Graham-Number | 2.75 | |||||
Price-to-Net-Current-Asset-Value | 3.22 | |||||
Price-to-Net-Cash | 28.75 | |||||
Earnings Yield (Greenblatt) % | 1.42 | |||||
FCF Yield % | 0.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Dabomb Protein Biotech Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 356.75 | ||
EPS (TTM) (NT$) | 0.13 | ||
Beta | 0.84 | ||
Volatility % | 35 | ||
14-Day RSI | 30.55 | ||
14-Day ATR (NT$) | 0.435846 | ||
20-Day SMA (NT$) | 19.0825 | ||
12-1 Month Momentum % | -7.75 | ||
52-Week Range (NT$) | 18.15 - 33.9 | ||
Shares Outstanding (Mil) | 67.99 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Dabomb Protein Biotech Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Dabomb Protein Biotech Corp Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
Dabomb Protein Biotech Corp Frequently Asked Questions
What is Dabomb Protein Biotech Corp(ROCO:6578)'s stock price today?
When is next earnings date of Dabomb Protein Biotech Corp(ROCO:6578)?
Does Dabomb Protein Biotech Corp(ROCO:6578) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |